We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Rapid Bedside Test to Protect Newborns from Life-Threatening Illnesses

By LabMedica International staff writers
Posted on 04 Jan 2024

Group B Streptococcus (GBS), a bacterial strain, is the leading cause of severe infections in newborns in the UK. More...

Around one in four pregnant women in the UK are carriers of GBS, often unknowingly, and during childbirth, there's a 50% chance of transmitting the bacteria to the baby. While most exposed infants remain healthy, approximately one in 1,750 will develop early-onset GBS infections, including sepsis, pneumonia, or meningitis, which can have severe consequences. The UK currently employs a 'risk factor-based screening' approach, providing antibiotics during labor to women identified with GBS during pregnancy or those with a previous baby affected by GBS. However, this strategy fails to detect many GBS carriers, with about 65% of early-onset GBS infections in newborns occurring in babies whose mothers had no identified risk factors. Now, a research project is examining the potential of a rapid bedside test for safeguarding newborns from life-threatening illnesses transmitted during birth.

The GBS3 study, conducted by the University of Nottingham (Nottingham, UK), has so far recruited over 1,100 pregnant women across the UK. The research aims to determine whether universally screening pregnant women for GBS can reduce the incidence of newborn infections. The study compares two methods: a test during a prenatal visit around 36 weeks of pregnancy and a quick bedside test conducted as labor begins that delivers results in about 40 minutes. Upon positive results, antibiotics are administered to protect the newborn from potential illness. The study, set to recruit until March 2024, is being conducted in 71 hospitals across England, Wales, and Scotland, out of which 17 sites are equipped for rapid testing.

“This is the first trial of its kind in the world and the results will help to determine whether routine testing should be introduced in the UK,” said Mr. Sachchidananda Maiti, consultant obstetrician, who is leading the study in the North Manchester maternity unit. “Identifying women with GBS with greater accuracy and treating them with antibiotics at the optimum time, could prevent approximately 40 newborn deaths and 25 cases of disability in the UK each year.”

Related Links:
University of Nottingham 


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Rapid Sepsis Test
SeptiCyte RAPID
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Molecular Diagnostics

view channel
Image: Spatial profiling of muscle-invasive bladder cancer reveals how distinct tumor cell states are organized within individual tumors (Image Credit: Shutterstock)

Spatial Map Guides Treatment Selection in Muscle-Invasive Bladder Cancer

Muscle-invasive bladder cancer is clinically heterogeneous, with patients often responding very differently to therapy. Existing biomarkers do not fully explain these disparities, limiting precision treatment... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.